Background-Primary amyloidosis has a poor prognosis as a result of frequent cardiac involvement. We recently reported a high prevalence of intracardiac thrombus in cardiac amyloid patients at autopsy. However, neither the prevalence nor the effect of anticoagulation on intracardiac thrombus has been evaluated antemortem. Methods and Results-We studied all transthoracic and transesophageal echocardiograms of cardiac amyloid patients at the Mayo Clinic. The prevalence of intracardiac thrombosis, clinical and transthoracic/transesophageal echocardiographic risks for intracardiac thrombosis, and effect of anticoagulation were investigated. We identified 156 patients with cardiac amyloidosis who underwent transesophageal echocardiograms. Amyloidosis was the primary type (AL) in 80; other types occurred in 76 patients, including 56 with the wild transthyretin type, 17 with the mutant transthyretin type, and 3 with the secondary type. Fifth-eight intracardiac thrombi were identified in 42 patients (27%). AL amyloid had more frequent intracardiac thrombus than the other types (35% versus 18%; Pϭ0.02), although the AL patients were younger and had less atrial fibrillation. Multivariate analysis showed that atrial fibrillation, poor left ventricular diastolic function, and lower left atrial appendage emptying velocity were independently associated with increased risk for intracardiac thrombosis, whereas anticoagulation was associated with a significantly decreased risk (odds ratio, 0.09; 95% CI, 0.01 to 0.51; PϽ0.006). Conclusions-Intracardiac thrombosis occurs frequently in cardiac amyloid patients, especially in the AL type and in those with atrial fibrillation. Risk for thrombosis increased if left ventricular diastolic dysfunction and atrial mechanical dysfunction were present. Anticoagulation therapy appears protective. Timely screening in high-risk patients may allow early detection of intracardiac thrombus. Anticoagulation should be carefully considered. (Circulation.
A myloidosis is an uncommon condition. It is estimated that there are 1275 to 3200 new cases annually in the United States on the basis of incidence data from a large ongoing cardiovascular epidemiology study in Olmsted County, Minn. 1, 2 Amyloidosis is classified by the precursor plasma proteins that form the extracellular fibril deposits. The primary systemic type, AL, is due to monoclonal immunoglobulin free light chains; the hereditary (also known as familial) type is due to mutant transthyretin (or mutant TTR) deposition; the wild-type transthyretin type (wild-type TTR, or "senile" type) is due to normal wild-type transthyretin deposition; and the secondary type (AA type) is related to amyloid A protein, which is an acute reactive protein. 2, 3 Amyloidosis, especially the AL type, frequently involves the heart and causes arrhythmias, heart failure (HF) with prominent left ventricular (LV) diastolic dysfunction, and sudden cardiac death. 4, 5 In part because of cardiac involvement, AL amyloidosis has the worst prognosis, with a median survival of 6 months when HF is present. 2, [5] [6] [7] 
Clinical Perspective on p 2497
We and others have identified a high prevalence of intracardiac thrombosis in these patients at autopsy, especially in AL cardiac amyloidosis. 4, 8 Furthermore, in our autopsy series, systemic embolism was a significant cause of mortality. 8 However, it is possible that autopsy series may overemphasize the frequency of intracardiac thrombosis, and there have been only a few anecdotal reports in the literature on intracardiac thrombosis detected by transesophageal echocardiogram (TEE) or transthoracic echocardiogram (TTE) in live patients. 9 -15 Thus, the prevalence of intracardiac thrombus and the effects of anticoagulation in living cardiac amyloid patients have not been described. Accordingly, we evaluated both TTE and TEE studies from patients with various types of cardiac amyloidosis to determine how frequently detectable intracardiac thrombi are present, the clinical and echocardiographic characteristics associated with their presence, and the effects of therapeutic anticoagulation.
Methods

Study Groups
We searched the Mayo Clinic Hematology Database for all cases of amyloidosis from 1999 to 2007. There were 1909 cases with either a definite diagnosis of amyloidosis or suspected amyloidosis. This data set was then matched with the TEE database. There were 426 of 1909 patients who underwent TEE studies. Patients were included in the study if they had a positive cardiac biopsy for amyloid regardless of TEE or TTE findings or, for patients who had systemic amyloid as evidenced by positive noncardiac tissue biopsies (such as fat, bone morrow, gastrointestinal tract, liver, and kidney), if they also had a typical cardiac amyloid appearance on echocardiogram or MRI that could not be explained by another comorbidity such as hypertension, LV outflow tract obstruction, or aortic stenosis. Of the 426 patients, 156 met the above criteria and were included in this study. Eightyseven patients (56%) had positive cardiac amyloid biopsy, and the remaining 69 patients met the second criterion given above.
We excluded 270 patients in whom there was no evidence of amyloidosis (who were included in the initial list because of the term rule out amyloidosis or cerebral amyloid angiopathy in electronic medical record system [215 of 270, 80%] or who had amyloidosis in another organ system but no evidence of cardiac involvement [48 of 270, 18%]). The study was approved by the Mayo Clinic Institutional Review Board.
Clinical Data
Clinical information, including demographic data, comorbidities, presence of HF, New York Heart Association (NYHA) functional class, and use of anticoagulants before and at the time of TEE, ECG, TTE, TEE, and MRI, and other laboratory data were abstracted from clinical records. Cardiac rhythm was determined from the patient's ECG, Holter monitoring data, and medical records. International normalized ratio and activated partial thromboplastin time around the time of TEE were charted. Therapeutic anticoagulation was defined as an international normalized ratio Ն2 at the time of TEE, Ն2 documented consecutive therapeutic international normalized ratios of 2 to 3 before TEE for those with long-term anticoagulation, or at least 48 hours of intravenous heparin therapy or 48 hours of subcutaneous low-molecular-weight heparin therapy before TEE. Other abstracted information included results of tissue biopsies, urine and serum protein electrophoresis, immunofixation, serum free light chain assay, genetic testing, and family history.
Echocardiograms
TTE and TEE studies were reviewed independently by 2 of the authors (D.F. and I.S.S.) who had no knowledge of the clinical and pathological data. Inconsistencies between the reports and reviews were adjudicated by a third cardiologist (K.W.K.). TTE methods have been described in detail elsewhere. 8 Briefly, TTE parameters extracted included LV ejection fraction; LV end-diastolic diameter; LV end-systolic diameter; stroke volume; ventricular septum thickness; LV posterior wall thickness; right ventricular free wall thickness; right ventricular systolic pressure; left atrial (LA) volume index; right atrium (RA) enlargement (0ϭnormal, 1ϭmild, 2ϭmod-erate, 3ϭsevere); LV diastolic function grade classified on the basis of mitral inflow pattern, mitral tissue Doppler, and pulmonary venous flow pattern 16 ; mitral inflow E and A velocities; deceleration time; mitral septal annulus tissue Doppler velocity (systolic peak velocity, sЈ; early peak diastolic velocity, eЈ; late peak diastolic velocity, aЈ); and pulmonary venous flow profile (peak systolic velocity [S] , peak diastolic velocity [D] , D/S, and atrial contractile velocity), E/A, and E/eЈ. 16 The TEE studies were reviewed for the presence or absence of intracardiac thrombus and their location and size. 16 LA appendage (LAA) and LA spontaneous contrast and their severity were semiquantified as none, mild, moderate, or severe (0, 1, 2, or 3, respectively). 17 LAA emptying velocity was measured by pulse Doppler echocardiography as previously reported. 17 The degree of atherosclerosis in aorta was semiquantified as none, mild, moderate, or severe. 18, 19 Heart rate and blood pressure (BP) at the time of TEE were documented.
Pathology Data
The presence of cardiac or other tissue amyloid deposition was reconfirmed by review of the Congo red-or sulfated Alcian blue-stained specimen. Amyloid subtype was determined immunohistochemically with antibodies against serum amyloid P component, , and free immunoglobulin light chains, transthyretin (TTR; prealbumin), amyloid A component, and ␤-2 microglobulin.
Statistical Analysis
Data are expressed as meanϮSD for continuous data and percent for ordinal and categorical data. Unpaired Student's t tests were used to compare continuous variables. 2 Tests were used to compare categorical data and ordinal variables. Univariate and multivariate analyses were performed to identify factors associated with intracardiac thrombosis. Ordinal variables such as spontaneous contrast in the LAA were treated as categorical variables in these analyses. Multivariate analysis was performed with logistic regression. Variables with a value of PՅ0.05 in univariate analysis were considered significant and included in multivariate analyses by the use of several models, including the clinical variables model, TTE variables model, and TEE variables model. Nonsignificant variables were removed. Variables that were statistically significantly associated with intracardiac thrombosis by the above 3 models were then included in a final combined model. Finally, forward stepwise multivariate analyses were also performed, with values of PՅ0.05 regarded as statistically significance in each step and included in the model for further analysis. Results for multivariate analyses were reported with the odds ratio, 95% CI, and probability value.
The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Demographic Data and Amyloid Subtypes
Amyloidosis was the AL type in 80, the wild TTR type in 56, the mutant TTR type in 17, and the AA type in 3. Because AA is rare, patients with the AA type were combined into 1 group with the patients with the wild and mutant TTR cases (called other amyloidosis; nϭ76). Compared with the other amyloid group, the AL group was younger, had fewer male patients, had less atrial fibrillation (AF), were less often receiving anticoagulation therapy, were less often had a history of hypertension, and were more likely to be treated with stem cell transplantation (all PՅ0.05; Table 1 ). There was no significant difference in history of HF, NYHA class, or other variables between the 2 groups listed in Table 1 (all PϾ0.05).
Indications for TEE
TEE was performed in 57 patients (37%) for AF and/or before direct-current cardioversion in 33 patients (21%) to search for the source for embolism, in 14 patients (9%) to evaluate valvular heart disease, in 12 patients (8%) to rule out endocarditis, and in 6 patients (4%) for other reasons. TEE was performed prospectively in 34 cardiac amyloid patients (22%) after our initial autopsy observations at the discretion of referral hematologists or cardiologists. All TEE studies were performed without major complications or mortality. All patients with TEE except 1 also had TTE studies.
Intracardiac Thrombus
Fifty-eight intracardiac thrombi were identified in 42 of 156 patients (27%) by TEE. Most patients with thrombi (30 patients, 71%) had 1 thrombus, whereas 8 patients (19%) had 2 thrombi, and 4 patients (10%) had 3. Most clots occurred in the LAA (nϭ32) or in the RA appendage (nϭ19). Of all of these thrombi detected by TEE, only 3 were detected by TTE. There was a significant difference in the frequency of intracardiac thrombosis between patients with AL amyloidosis and the other types (35% versus 18%; Pϭ0.02). The frequencies for intracardiac thrombosis were 18% for the wild TTR type, 17% for the mutant TTR type, and 33% for the AA type.
The frequency of intracardiac thrombi in those receiving therapeutic anticoagulants was only 13%, much lower than in those not on therapeutic anticoagulant therapy at the time of TEE studies (37%; Pϭ0.001). We further analyzed these patients on chronic anticoagulation with therapeutic international normalized ratio at the time of TEE with stratifying findings according to persistent or permanent AF versus non-AF. Chronic anticoagulation was associated with a significantly lower risk for intracardiac thrombosis (prevalence, 18% [6 of 33] versus 50% [13 of 26] in those who were not on anticoagulation; Pϭ0.01). A similar trend was observed for patients who had no AF, with a respective intracardiac thrombosis prevalence of 0% (0 of 12) in the chronic anticoagulation group versus 20% (8 of 40) in the group with no anticoagulation (Pϭ0.09).
Clinical Characteristics and Thrombosis
Compared with the group without thrombosis, the intracardiac thrombosis group was younger, had more AF, but was less apt to be receiving therapeutic anticoagulation (Table 2) . They were also more likely to have AL amyloidosis, a lower systolic BP, and a faster heart rate (all PՅ0.05). Similar results were obtained after the exclusion of patients who had 
TTE and Thrombosis
The group with thrombi had a smaller LV end-diastolic dimension, thicker LV posterior wall, larger RA size, smaller stroke volume and cardiac index, lower LV ejection fraction, worse LV diastolic function, shorter deceleration time, poorer LA mechanical activity (lower A and aЈ velocity), and higher E/A and E/eЈ than the nonthrombotic group. Furthermore, pulmonary vein peak systolic velocity and A velocity were significantly lower and D/S was higher (all PՅ0.05). LA volume index was not statistically different. After exclusion of AF patients, the differences in several TTE parameters between the thrombosis group and the nonthrombosis group were no longer statistically different, although the trends were similar (Table 3) . No significant differences existed in intracardiac thrombosis between LV diastolic function grade 2 and grade 1 (0% 
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TEE and Thrombosis
Those with intracardiac thrombi more frequently had spontaneous echo contrast in the LA, more severe spontaneous echo contrast in both the LA and LAA, and lower LAA emptying velocity compared with the nonthrombotic group. Similar results were obtained after the exclusion of patients who had AF. There was no difference in the degree of atherosclerosis in aorta (Table 4) .
Multivariate Analysis and ROC
By multivariate analysis, AF, therapeutic anticoagulation, and lower systolic BP were independently associated with intracardiac thrombosis, whereas there was a borderline trend for AL type in the model when only clinical variables were used (Table 5) . For TTE variables, LV diastolic function was the only variable independently associated with intracardiac thrombosis. Comparing restrictive filling with nonrestrictive filling LV diastolic function, we obtained an odds ratio of 10.6 (95% CI, 1.5 to 220.3; Pϭ0.04). For TEE variables, the only independent variable associated with intracardiac thrombosis was LAA emptying velocity. When clinical, TTE, and TEE variables that were statistically significant by the above 3 models were included in the final model, AF, anticoagulation therapy, LV diastolic function, and LAA emptying velocity were independently associated with intracardiac thrombosis. Forward stepwise multivariate analysis was performed, with the inclusion of age, gender, amyloid type, AF, anticoagulation therapy, heart rate, systolic BP, LAA spontaneous contrast, LAA emptying velocity, LV ejection fraction, LV diastolic function, A velocity, and stroke volume as dependent variables. LAA emptying velocity, LV diastology, and AF were independently associated with increased risk for intracardiac thrombosis (PϽ0.0001, Pϭ0.002, and Pϭ0.04, respectively), whereas systolic BP showed a trend (Pϭ0.12) but anticoagulation therapy was no longer statistically significant (Pϭ0.18). A receiver-operating characteristics analysis for LAA emptying velocity to predict intracardiac thrombosis was performed. With 15 cm/s as the cutoff, LAA emptying velocity had a sensitivity of 70% and a specificity of 73%. With 23 cm/s as the cutoff, which is comparable to that reported previously, 17 the sensitivity increased to 100%, but the specificity decreased to 53%. The area under the curve was 0.81. Using grade 3 as a cutoff value for LV diastolic function had a sensitivity of 92% and a specificity of 59%. The area under the curve was 0.82. Multivariate analysis with AF, LAA emptying velocity, and LV diastolic function as dependent variables increased the area under the curve to 0.85. When further stratifying thrombosis risk on the basis of LAA emptying velocity and LV diastolic function, we found 0% intracardiac thrombosis in patients with LAA emptying ve- locity Ͼ15 cm/s and LV diastolic function grade Յ2, 26% in patients with either LAA emptying velocity Յ15 cm/s or LV diastolic grade 3 or 4, and 67% in patients who had both (PϽ0.0001). Similar results were obtained after further stratification by AF. The respective prevalence of intracardiac thrombosis was 0%, 15%, and 50% for non-AF patients (Pϭ0.02) and 0%, 32%, and 72% for AF patients (Pϭ0.002), respectively.
Twenty-three patients underwent TEE-guided cardioversion. Four patients failed cardioversion after multiple trials; 19 patients were initially successfully converted to sinus rhythm. Seven patients did not have follow-up. For the remaining 12 patients, the median time to recurrent AF was 2 months (25% to 75% in the quartile of 0.5 to 11 months). Only 3 patients remained in sinus rhythm for Ͼ12 months. Symptomatic improvement was noted in 5 patients after cardioversion.
Discussion
Our data from a large TEE study of patients with different types of cardiac amyloidosis confirm our previous autopsy study describing a high frequency of intracardiac thrombosis. We were able to identify that AF, poor LV diastolic function, and LA mechanical dysfunction as indicated by a low LAA emptying velocity were independent predictors of intracardiac thrombosis. Furthermore, it appears from our data that therapeutic anticoagulation therapy protects against intracardiac thrombosis. Low systolic BP also was independently associated with increased risk for intracardiac thrombosis, whereas the AL type of cardiac amyloidosis had a borderline trend when only clinical variables were considered for multivariates analyses.
Intracardiac Thrombosis in Cardiac Amyloidosis
Our TEE study confirms the observations of Roberts and Waller 4 and our prior autopsy study that showed a high prevalence of intracardiac thrombosis in cardiac amyloidosis. AL type was associated with a 35% prevalence of intracardiac thrombosis compared with 18% in the other amyloid groups despite the fact that the other amyloid groups were older and more frequently had AF. The prevalence of intracardiac thrombosis in TTR-related amyloid (either wild or mutant TTR) is comparable to that reported in the AF population without anticoagulation. 20 -22 In comparison, AL patients have a higher prevalence of intracardiac thrombosis than that reported in the general nonamyloid AF population. 20 -22 In fact, the prevalence of intracardiac thrombosis is comparable to that reported in patients with severe mitral valve stenosis with AF, which had the highest prevalence of intracardiac thrombosis (33%). 23 
Clinical Variables and Intracardiac Thrombosis
Several studies have shown that advanced age, HF, diabetes, and hypertension are risk factors for thromboembolism and thus presumably increased risk for intracardiac thrombi in nonamyloid AF patients. 24, 25 In our present study, AF and low systolic BP were independently associated with thrombosis. A low systolic BP may reflect a low cardiac output status and severe amyloid heart disease with cardiac decompensation.
Most important, we identified that therapeutic anticoagulation was significantly associated with a decreased risk for intracardiac thrombosis by both univariate and multivariate analyses.
Clinical HF and NYHA class were not significantly different in patients with or without thrombosis as observed in prior study. 8 Because many patients were elderly with multiple comorbidities, the clinical diagnosis of HF or NYHA class is a subjective indicator of overall well-being and may not always be accurate for grading the severity of HF. Moreover, other traditional risk factors for thromboembolism such as age, diabetes, and hypertension were not significantly associated with intracardiac thrombosis. We speculated that risk factors with only modest effect could not be detected in this special study population in which overwhelming effects from AL type, AF, and anticoagulation therapy are likely to have masked their modest effects.
TTE, TEE Characteristics, and Intracardiac Thrombosis
Univariate analysis showed that the group with thrombi had evidence of more advanced cardiac amyloid deposition as indicated by a smaller LV end-diastolic dimension, thicker LV wall, poorer LV systolic and diastolic function, higher LV filling pressure estimated by E/eЈ, and less LA mechanical activity than the group without thrombi. Furthermore, LA and LAA spontaneous contrast were present more often and were more pronounced in those with intracardiac thrombi. Similar TTE and TEE results were obtained after exclusion of AF patients. Therefore, AF plays only a partial role for intracardiac thrombosis. Multivariate analyses showed that only 2 echocardiography variables, LV diastolic dysfunction and low LAA emptying velocity, were, in addition to AF, independently associated with intracardiac thrombosis. The observation was not surprising because LV diastolic function is graded on the basis of several TTE features, including mitral inflow profile and mitral annulus tissue Doppler, whereas LAA emptying velocity directly reflects LAA mechanical function.
Our present and prior studies support the hypothesis that the combination of systolic and diastolic ventricular dysfunction and chronic amyloid infiltrate in the atria leads to atrial mechanical dysfunction, 15, 26 atrial enlargement, and blood stasis. 27, 28 Such atrial electrical-mechanical dissociation at least partially explains why some cardiac amyloid patients developed atrial thrombosis while in sinus rhythm. 15, 26, 29 It is possible that endomyocardial damage and endothelial dysfunction from amyloid depositions and hypercoagulability may also contribute, although the data to support these hypotheses have been limited. 7,30 -32 
Anticoagulation and Intracardiac Thrombosis
We identified that therapeutic anticoagulation therapy at the time of TEE was associated with a significantly lower risk for intracardiac thrombosis. Thus, effective anticoagulation might reduce thromboembolism, which is a significant contributor to mortality in cardiac amyloid patients. 8 However, anticoagulation may exacerbate the hemorrhagic tendency, which is a well-known complication of amyloidosis, because of fragile blood vessel walls secondary to amyloid deposition and the coexisting coagulopathy in such patients. 2, 32 In our prior autopsy series, 3 cardiac amyloid patients died of massive gastrointestinal bleeding. 8 Therefore, the potential benefits of anticoagulation must be carefully weighed against possible hemorrhagic complications before anticoagulation is initiated.
Further Directions
A recent study suggests that chemotherapy in AL patients with cardiac involvement results in a clinical improvement despite an unchanged TTE appearance. 33 Improvement may be due to the abolition of the production of new light chains, which are toxic to myocardium by increasing oxidant stress and causing diastolic dysfunction. 34, 35 Furthermore, there has been report of echocardiographic improvement and decreased amyloid accumulation by 99m Tc-PYP scintigram after chemotherapy and stem cell transplantation. 36 Therefore, it is possible that early detection of amyloidosis, vigilant screening for intracardiac thrombosis with early anticoagulation, and more aggressive treatment of the underlying plasma dyscrasia might improve the prognosis. 3, 28, 37, 38 However, a prospective study to specifically address the issue of intracardiac thrombosis and anticoagulation is needed before a definite recommendation can be made.
Study Strengths and Limitations
We evaluated a large series of cardiac amyloidosis in which the majority had cardiac biopsy. Furthermore, all patients except 1 had both TEE and TTE studies performed. We routinely evaluate diastolic function in all TTE studies performed in our laboratory. However, this study has several limitations. First, the high frequency of intracardiac thrombosis could be partially related to referral bias because most TEE studies were performed as a result of the presence of AF or in an attempt to discern a source for embolization. It has been reported that the prevalence of AF in AL and familial amyloidosis was 19% to 45%. 8,39 -41 Thus, our patients had more prevalent AF and may have had more advanced cardiac amyloid involvement as indicated by TTE. Our observation may not apply to early-stage amyloidosis or the general cardiac amyloidosis population. Most likely, the prevalence of intracardiac thrombosis would be much lower in earlystage cardiac amyloidosis because of better cardiac diastolic function, preserved LA/LAA contractility, and less AF. Interestingly, however, there was no significant difference in the prevalence of thrombosis between the groups evaluated retrospectively and those evaluated prospectively, although the prospective group was of modest size (nϭ34). Second, the frequency of thrombosis and embolism could have been underestimated because small emboli may be clinically silent and may have been overlooked, especially in the RA appendage. Finally, although our study is the only large series study on intracardiac thrombosis in living cardiac amyloid patients, our sample size of 156 subjects may have lacked the power to detect factors that have only modest effects on intracardiac thrombosis.
Conclusions
This study demonstrated a high frequency of intracardiac thrombosis in patients with cardiac amyloidosis, especially in the AL type. AF, poor LV diastolic function, and poor atrial mechanical function were independently associated with increased risk for intracardiac thrombosis. Importantly, therapeutic anticoagulation therapy appeared protective against intracardiac thrombosis. Early screening for intracardiac thrombosis by TEE, especially in the high-risk patient as identified in our study, may be indicated. If intracardiac thrombosis or severe LAA mechanical dysfunction (especially with coexisting restrictive LV filling) is detected, anticoagulation should be carefully considered.
